Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies

Attia, Noha; Mashal, Mohamed; Pemminati, Sudhakar; Omole, Adekunle Ebenezer; Edmondson, Carolyn K; Jones, W. K.; Priyadarshini, Priyanka; Mughal, Temoria; Aziz, Pauline; Zenick, Blesing; Perez, Ambar; Lacken, Morgan

doi:10.3390/cells11010116

Cited by 12 publications

(20 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human T cells are lymphocytes that belong to the adaptive immune system. So far, majority of the GBM CAR T therapies have been autologous treatments with single or multiple dose (3)(4)(5)(6) infusions. This approach features the delivery routes of CAR T cells which are intracranial at the tumor site (ICT), intracranial into the ventricles (ICV) and intravascular (IV) administration (34).…”

Section: Chimeric Antigen Receptor (Car) T Cellsmentioning

confidence: 99%

“…In addition to NSCs, another type of adult stem cell, the mesenchymal stem cell, is being widely tested in the treatment of GBM. MSCs are multipotent stem cells that can be obtained from bone marrow, peripheral blood, adipose tissue, umbilical cord, cord blood, dental pulp, et al (6). They are spindle-shaped cells which can be relatively easily isolated, expanded extensively during in vitro culture while maintaining their potential to generate different types of cells (141).…”

Section: Adult Stem Cellsmentioning

confidence: 99%

“…If any progress is made, it is negated by the rapid growth rate of the returning tumors ( 5 ). The existence of the blood–brain barrier (BBB) also adds a layer of difficulty because BBB reduces the bioavailability of systemically administered drugs within the central nervous system (CNS) ( 6 ). To compound the treatment difficulties, the established therapies mentioned above are joined by the newer immunotherapies in their ineffectiveness against GBM resistance.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Advanced Cell Therapies for Glioblastoma

Wang¹,

Wang²

2022

Front. Immunol.

View full text Add to dashboard Cite

The sheer ubiquity of Gioblastoma (GBM) cases would lead you to believe that there should have been many opportunities for the discovery of treatments to successfully render it into remission. Unfortunately, its persistent commonality is due in large part to the fact that it is the most treatment-resistant tumors in adults. That completely changes the treatment plan of attack. Long established and accepted treatment therapies such as surgical resection, radiation, and aggressive chemotherapy, (and any combination thereof) have only confirmed that the disease lives up to its treatment-resistant reputation. To add to the seemingly insurmountable task of finding a cure, GBM has also proven to be a very stubborn and formidable opponent to newer immunotherapies. Across the board, regardless of the therapy combination, the five-year survival rate of GBM patients is still very poor at a heartbreaking 5.6%. Obviously, the present situation cannot be tolerated or deemed acceptable. The grave situation calls for researchers to be more innovative and find more efficient strategies to discover new and successful strategies to treat GBM. Inspired by researchers worldwide attempting to control GBM, we provide in this review a comprehensive overview of the many diverse cell therapies currently being used to treat GBM. An overview of the treatments include: CAR T cells, CAR NK cells, gamma-delta T cells, NKT cells, dendritic cells, macrophages, as well stem cell-based strategies. To give you the complete picture, we will discuss the efficacy, safety, and developmental stages, the mechanisms of action and the challenges of each of these therapies and detail their potential to be the next-generation immunotherapeutic to eliminate this dreadful disease.

show abstract

Section: Chimeric Antigen Receptor (Car) T Cellsmentioning

confidence: 99%

Section: Adult Stem Cellsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Cell Therapies for Glioblastoma

Wang¹,

Wang²

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…On the other hand, BBB is composed of endothelial cells with tight junctions and adhesion molecules that forms a barrier between blood and brain extracellular fluid. BBB serves as an obstacle to many small and large molecules, including drugs and other therapeutic agents ( Patel and Patel, 2017 ; Attia et al, 2021 ). To better cross BBB, either BBB must get more permeable, or the approach to drug delivery must be modified ( Hsu et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Allami

Heidari²,

Rezaei³

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Glioblastoma multiform (GBM) is the most prevalent and deadliest primary brain malignancy in adults, whose median survival rate does not exceed 15 months after diagnosis. The conventional treatment of GBM, including maximal safe surgery followed by chemotherapy and radiotherapy, usually cannot lead to notable improvements in the disease prognosis and the tumor always recurs. Many GBM characteristics make its treatment challenging. The most important ones are the impermeability of the blood-brain barrier (BBB), preventing chemotherapeutic drugs from reaching in adequate amounts to the tumor site, intratumoral heterogeneity, and roles of glioblastoma stem cells (GSCs). To overcome these barriers, the recently-developed drug-carrying approach using nanoparticles (NPs) may play a significant role. NPs are tiny particles, usually less than 100 nm showing various diagnostic and therapeutic medical applications. In this regard, cell membrane (CM)-coated NPs demonstrated several promising effects in GBM in pre-clinical studies. They benefit from fewer adverse effects due to their specific targeting of tumor cells, biocompatibility because of their CM surfaces, prolonged half-life, easy penetrating of the BBB, and escaping from the immune reaction, making them an attractive option for GBM treatment. To date, CM-coated NPs have been applied to enhance the effectiveness of major therapeutic approaches in GBM treatment, including chemotherapy, immunotherapy, gene therapy, and photo-based therapies. Despite the promising results in pre-clinical studies regarding the effectiveness of CM-coated NPs in GBM, significant barriers like high expenses, complex preparation processes, and unknown long-term effects still hinder its mass production for the clinic. In this regard, the current study aims to provide an overview of different characteristics of CM-coated NPs and comprehensively investigate their application as a novel treatment approach in GBM.

show abstract

“…Current therapy only minimally improves the median survival time of patients, from 12 months to 14.6 months, while the 5-year survival rate of treated patients is less than 10% [ 24 ]. As a result, there is an imperative need for the development of new therapies that are targeted and effectively effective in the treatment of glioblastoma [ 25 ]. Typically, the challenges raised by glioblastoma are found in the molecular and genetic signaling pathways happening in this type of cancer [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas

Persano

Gigli

Leporatti

2022

IJMS

View full text Add to dashboard Cite

In humans, glioblastoma is the most prevalent primary malignant brain tumor. Usually, glioblastoma has specific characteristics, such as aggressive cell proliferation and rapid invasion of surrounding brain tissue, leading to a poor patient prognosis. The current therapy—which provides a multidisciplinary approach with surgery followed by radiotherapy and chemotherapy with temozolomide—is not very efficient since it faces clinical challenges such as tumor heterogeneity, invasiveness, and chemoresistance. In this respect, natural substances in the diet, integral components in the lifestyle medicine approach, can be seen as potential chemotherapeutics. There are several epidemiological studies that have shown the chemopreventive role of natural dietary compounds in cancer progression and development. These heterogeneous compounds can produce anti-glioblastoma effects through upregulation of apoptosis and autophagy; allowing the promotion of cell cycle arrest; interfering with tumor metabolism; and permitting proliferation, neuroinflammation, chemoresistance, angiogenesis, and metastasis inhibition. Although these beneficial effects are promising, the efficacy of natural compounds in glioblastoma is limited due to their bioavailability and blood–brain barrier permeability. Thereby, further clinical trials are necessary to confirm the in vitro and in vivo anticancer properties of natural compounds. In this article, we overview the role of several natural substances in the treatment of glioblastoma by considering the challenges to be overcome and future prospects.

show abstract

Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies

Cited by 12 publications

References 186 publications

Advanced Cell Therapies for Glioblastoma

Advanced Cell Therapies for Glioblastoma

The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma

Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas

Contact Info

Product

Resources

About